PolyPid Ltd. (NASDAQ:PYPD – Get Free Report) was the recipient of a large decrease in short interest during the month of April. As of April 30th, there was short interest totaling 30,140 shares, a decrease of 74.4% from the April 15th total of 117,650 shares. Based on an average daily volume of 42,887 shares, the days-to-cover ratio is presently 0.7 days. Currently, 0.2% of the shares of the company are short sold.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of the company. AIGH Capital Management LLC boosted its holdings in PolyPid by 18.7% in the 1st quarter. AIGH Capital Management LLC now owns 1,593,587 shares of the company’s stock worth $6,980,000 after buying an additional 250,615 shares during the period. XTX Topco Ltd raised its stake in PolyPid by 50.0% during the 4th quarter. XTX Topco Ltd now owns 32,661 shares of the company’s stock valued at $142,000 after purchasing an additional 10,888 shares during the period. ADAR1 Capital Management LLC bought a new stake in PolyPid during the 4th quarter valued at approximately $451,000. Jane Street Group LLC bought a new stake in PolyPid during the 4th quarter valued at approximately $66,000. Finally, HighTower Advisors LLC bought a new stake in PolyPid during the 4th quarter valued at approximately $44,000. Institutional investors own 26.47% of the company’s stock.
Analysts Set New Price Targets
PYPD has been the subject of several analyst reports. Weiss Ratings lowered PolyPid from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 1st. Wall Street Zen upgraded PolyPid from a “sell” rating to a “hold” rating in a research report on Saturday, March 14th. Finally, HC Wainwright reissued a “buy” rating and set a $13.00 price target on shares of PolyPid in a report on Wednesday, February 11th. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, PolyPid currently has a consensus rating of “Moderate Buy” and a consensus target price of $12.25.
PolyPid Stock Performance
Shares of PYPD traded down $0.34 during mid-day trading on Wednesday, reaching $4.22. The stock had a trading volume of 127,984 shares, compared to its average volume of 58,029. The firm has a market cap of $80.52 million, a price-to-earnings ratio of -1.87 and a beta of 1.41. PolyPid has a 12 month low of $2.44 and a 12 month high of $5.12. The business has a fifty day moving average of $4.39 and a 200 day moving average of $4.23.
PolyPid (NASDAQ:PYPD – Get Free Report) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.12. On average, research analysts forecast that PolyPid will post -1.5 EPS for the current fiscal year.
About PolyPid
PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.
Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.
Recommended Stories
- Five stocks we like better than PolyPid
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
- Plug Power Flips The Switch On Profitability
Receive News & Ratings for PolyPid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PolyPid and related companies with MarketBeat.com's FREE daily email newsletter.
